

Marker Proteins in Inflammation

Volume 2

Proceedings of the
Second Symposium
Lyon, France, June 27 – 30, 1983

Editors

P. Arnaud · J. Bienvenu · P. Laurent



Walter de Gruyter · Berlin · New York 1984

001476211
006336898
031241605

Editors

Philippe Arnaud, Ph. D., M. D.
Department of Basic and Clinical
Immunology and Microbiology
Medical University of South Carolina
171 Ashley Road
Charleston, South Carolina 29403
U.S.A.

Jacques Bienvenu, M. D.
Biochemical Laboratory
Hôpital Jules Courmont
F - 69310 Pierre Bénite
France

Philippe Laurent, M. D.
Department of Immunology
Institut Pasteur de Lyon
77, Rue Pasteur
F - 69365 Lyon Cedex 2
France



94 84 600

CIP-Kurztitelaufnahme der Deutschen Bibliothek

Marker proteins in inflammation: proceedings of the ... symposium.
- Berlin ; New York : de Gruyter
Vol. 2. Proceedings of the second symposium, Lyon, France,
June 27 - 30, 1983. - 1984.
ISBN 3-11-009872-5

Library of Congress Cataloging in Publication Data

Main entry under title:
Marker proteins in inflammation, volume 2.
Proceedings of the "Second Symposium sur les marqueurs de
l'inflammation," sponsored by the Groupe d'étude et de recherche
sur les marqueurs de l'inflammation (GERMI)
Bibliography: p.
Includes indexes.
1. Inflammation--Congresses. 2. Proteins--Congresses.
I. Arnaud, P. (Philippe) II. Bienvenu, J. (Jacques), 1950- . III. Laurent,
P. (Philippe), 1949- . IV. Symposium sur les marqueurs de
l'inflammation (2nd : 1983 : Lyon, France) V. Groupe d'étude et de
recherche sur les marqueurs de l'inflammation (France) [DNLM:
1. Blood Proteins--diagnostic use--congresses. 2. Blood Proteins--
immunology--congresses. 3. Inflammation--congresses.
QZ 150 M345 1983] RB131.M353 1984 616'.0473 84-9462
ISBN 3-11-009872-5

Copyright © 1984 by Walter de Gruyter & Co., Berlin 30.
All rights reserved, including those of translation into foreign languages. No part of this book may
be reproduced in any form - by photoprint, microfilm or any other means nor transmitted nor
translated into a machine language without written permission from the publisher. Printing:
Gerike GmbH, Berlin. - Binding: Dieter Mikolai, Berlin. Printed in Germany.

PREFACE

In the last week in June 1983, more than 250 research scientists and clinicians met at the Faculté Alexis Carrel, a School of Medicine (University, Claude Bernard, Lyon-I) located in Lyon, France. The participants had come from fifteen countries to participate in the "Second Symposium sur les Marqueurs de l'Inflammation" under the sponsorship of the "Groupe d'Etude et de Recherche sur les Marqueurs de l'Inflammation" (GERMI). The topics for this second symposium had been chosen by the International Scientific Committee of GERMI in order to provide a comprehensive view of the different aspects of the wide field of Marker Proteins in Inflammation and their clinical implications.

The proceedings begins with a series of papers concerning the mechanism of Acute Phase Reactant Proteins synthesis and the roles such proteins play in host defenses, a subject of perennial interest which was the main theme running throughout the meeting. The next three sections are devoted respectively to the protease anti-protease interplay in lung diseases, the importance of Acute Phase Proteins measurement in biological fluids for the diagnosis of joint diseases, and diseases of the central nervous system. The fourth section of the book deals with the role of zinc, protein deprivation, and malnutrition in host defenses. The fifth section features a group of papers on animal models of inflammation. Finally, the last section of the book reports on conferences held during a satellite lectins workshop arranged by Drs. Michel Caron et Alain Faure, which was devoted to three complementary aspects of lectins: their use as a tool for the study of glycoconjugates, their biological functions, and their affinity and specificity.

We wish to express our deepest gratitude to Professor Frank W. Putnam of the department of Molecular Biology and Biochemistry, Indiana University (Bloomington, Indiana, USA) who was the outstanding president

of this Symposium. We also want to extend our thanks to Professor Henry Gewurz, department of Immunology/Microbiology, Rush Medical College (Chicago, USA), Professor Robert Engler, department of Biochemistry, UER des Saints Pères (Paris, France) and Professor Roger Creyssel, department of Biochemistry UER Grange Blanche (Lyon, France), who acted as Symposium Co-Presidents and whose knowledge and understanding in the field made the program and its conferences possible.

We wish to thank the members of the Organizing Committee for their support and help. This includes Helene Bernon, Jacques Bienvenu, Philippe Laurent, Abel Rouillet, and J.L. Touraine. The following institutions provided financial and practical support: GERMI, Institut Pasteur de Lyon et du Sud Est, Fondation Merieux, Société Française d'Immunologie, Association des Anciens Internes et Internes en Pharmacie de Lyon, Commission Médicale Consultative de Hospices Civils de Lyon, BioMerieux, Travenol France, Du Pont de Nemours, Hoechst-Behring, Boehringer Mannheim, Technicon, Roger Bellon. We would also like to express our sincere gratitude to Professor Maurice Carraz, Director of the Pasteur Institute of Lyon for his important help, and Dr. Charles Merieux, who hosted the International Scientific Advisory Committee of GERMI and organized the social events. We would like to express our thanks to all other individuals, companies and institutions who contributed to the success of the symposium.

The fact that expert researchers agreed to write papers on this rather new and important subject has made our job a considerable pleasure. We also extend our gratitude to the staff of Walter de Gruyter, Berlin, whose labors have led to the rapid publication of this second volume on Marker Proteins in Inflammation.

February 1984

P. Arnaud
J. Bienvenu
P. Laurent

CONTENTS

SECTION I THE INFLAMMATORY RESPONSE AND ACUTE PHASE REACTANT PROTEINS

Induction and Control of Acute Phase Reactant Synthesis I. Kushner	3
Use of Immunomorphological Methods and Hemolytic Plaque Tests to Investigate the Synthesis and Secretion of Plasma Proteins by the Liver Cells During the Acute Inflammatory Reaction G. Feldmann	15
Progress in Plasma Proteins: Recent Findings on the Structure of Ceruloplasmin F.W. Putnam	25
Recent Findings on the Isoelectric Points of Human C-Reactive Protein P. Laurent, D.L. Emerson, R.C. Allen, P. Arnaud	43
SAA is a more Sensitive Marker for Chronic Inflammatory Disease than C-Reactive Protein or α_1 -Acid Glycoprotein R.E. Chambers, J.T. Whicher	47
Elastase- α_1 Proteinase Inhibitor Complex (E- α_1 PI) and C-Reactive Protein (CRP): Early Indicators of Inflamma- tory Processes M. Jochum, K.H. Duswald, H. Dittmer, S. Neumann	51
Human Kallikrein-Kininogen-Kinins (KKK) System and Acute- Phase Reactant Proteins (APRP) in Humans Undergoing Extracorporeal Circulation (ECC) M.E. Faymonville, A. Adam, P. Malengreaux, J. Damas, P. Ers, M. Hulot, M. Lamy, J. Lecomte	57

VIII

Effect of Non Steroidal Anti-Inflammatory Drug (Niflumique Acide) on Acute Phase Protein Response.
P. Laurent, A. Delvil, J. Bienvenu, C. Lahet,
B. Colin, J.P. Rebattu, L.F. Perrin 71

Transcortin Activities, Cortisol and Progesterone in Pathological Sera: Inflammation, Septic Shock, Renal and Cardiac Diseases
H. Zouaghi, L. Savu, E.A. Nunez, A. Carli,
D. Kleinknecht, C. Guérot 75

Measurement of Human High Molecular Weight Kininogen (HMW-K) by Laser Nephelometry
A. Adam, G. Calay, P. Ers, H. De Hertogh 79

SECTION II BIOLOGICAL ROLES OF ACUTE PHASE
REACTANT PROTEINS

Functions of Acute Phase Proteins in the Inflammatory Response
J.T. Whicher 89

Interaction of the Acute Phase Reactants α_1 -Acid Glycoprotein, C-Reactive Protein and Serum Amyloid P-Component with Platelets and the Coagulation System
B.A. Fiedel 99

Monoclonal Antibodies as Probes of Complement Function
S. Ruddy 125

Modulation of Formation of the C3 Amplification Convertase of Human Complement by Acute Phase Proteins
E. Fischer, M. Pontet, F. Delers, N. Tran Quang,
M. Kazatchkine, R. Enler 135

Materno-Trophoblastic Relationship in Normal Human Pregnancy and Recurrent Spontaneous Abortion
W.P. Faulk, C.-J. Yeh, B.-L. Hsi 139

Chemotactic Factors in the Airspaces that may Modulate
Inflammation

H. Reynolds, C. Roth-Fouret 153

SECTION III PROTEASE ANTI-PROTEASE INTERACTIONS
AND LUNG DISEASES

Human α_1 -Antichymotrypsin: Purification, Properties and
Reactions with some Serine Proteases

A. Laine, A. Hayem, M. Davril 171

Alpha₁-Antitrypsin-Protease Interactions: The Biological
Aspect

P. Arnaud, E. Gianazza 181

On the Interaction Between Human Liver Cathepsin L and the
two Cysteine Proteinases Inhibitors Present in Human Serum

M. Pagano, R. Engler, F. Esnard, F. Gauthier 203

Modulation of Human Lymphocyte Responses by α_1 -Antitrypsin
and α_2 -Macroglobulin

J.-P. Revillard, G. Cordier, J. Bata, M. Latour 207

Mediators of Inflammation in Inflammatory Alveolitis

R.G. Crystal, J.F. Cordier 219

Idiopathic Pulmonary Fibrosis. Multiparametric Evaluation
of Alveolar Lymphocyte and Macrophage Activation

J.F. Mornex, G. Cordier, B. Lahneche, J. Pages,
P. Chauvot, J.M. Vergnon, T. Wiesendanger, R. Loire,
M. Vincent, J.F. Cordier, F. Mornex, J.-P.Revillard,
J. Brune 223

The Alpha₁ Proteinase Inhibitor of the Lower Respiratory
Tract. Effect of Cigarette Smoking

A. Pelletier, C. Boudier, G. Pauli, J.G. Bieth 227

Collagenolytic Enzymes and Fibrosis of the Lung

J.F. Cordier, O. Benzerara, Y. Lasne, J. Brune,
R. Touraine 231

Elastolytic Activities and Proteinase Inhibitors in
Sputum from Patients with Cystic Fibrosis

J.M. Tournier, J. Jacquot, E. Puchelle, P. Sadoul,
J.-P. Chazalotte 235

Serum Derived Proteins and Antibacterial Proteins in
Cystic Fibrosis Sputum

J. Jacquot, J.M. Tournier, E. Puchelle, P. Sadoul,
J.-P. Chazalotte 239

Alveolar Fibronectin and Interstitial Lung Diseases

N. Biot, D. Gindre, R. Harf, F. Maréchal, B. Vercoestre,
M. Perrin-Fayolle 243

Sarcoidosis: IgG, β_2 Microglobulin and Evolutivity.

D. Duchassaing, P. Leclerc, M. Cambillau, O. de Fenoyl,
M. Paris 247

 α_1 -Proteinase Inhibitor in Meconium from Healthy Infants
and Infants with Cystic Fibrosis

P. Lafont, Y. Barbier, M. Barbier, J. Mathian,
R.C. Boisson, I. Garcia, R. Gilly 251

Qualitative Analysis of Proteins of Alveolar Fluid: A
Study by Ultra-Thin Layer Immunoelectrophoresis and
Electrofocusing

C. Chapuis-Cellier, J.-F. Cordier, J.-M. Vergnon,
A. Penet, J. Brune 255

Protease-Antiprotease Imbalance in Lung Diseases

J.F. Mornex, R.G. Crystal 261

SECTION IV INFLAMMATION AND ARTICULAR DISEASES

The Acute Phase Response in Connective Tissue Disease	
I. Rowe	273

The GLA-Containing Protein of Bone	
P.D. Delmas	281

Role of an Acute Phase Reactant, Retroviral gp70, in Murine SLE	
S. Izui, I. Hara	295

Study of 8 Marker Proteins of Inflammation in Synovial Fluid and Serum of Patients with Joint Diseases	
P. Bourg, B. Cartier, M. Mathieu, C. Collombel	305

Fibronectin in Arthropathies	
J. Lecocq, N.Y. Lecocq, L. Asch, M. Roth, M.L. North	311

SECTION V INFLAMMATORY DISEASES OF NERVOUS SYSTEM

Multiple Sclerosis: Clues for a Pathogenesis	
C. Confavreux, P. Arnaud	319

Immunoglobulins in Neuropathology	
A. Lowenthal	339

Cellular Inflammatory Response in Cerebrospinal Fluids	
C. Caudie, O. Freney, F. Touraine	345

Evaluation of CSF Lymphocyte Subsets Using the OKT Series of Monoclonal Antibodies (OKT ₃₊ , OKT ₄₊ , OKT ₈₊) in Various Neurological Diseases	
G. Servoz, F. Touraine, C. Quincy	355

Cytological Study and Protein Profile in Cerebrospinal Fluid, Before and During Treatment of Neurosyphilis O. Freney, C. Caudie, S. Gas, C. Quincy	359
Cerebrospinal Fluid Cytology and Protein Parameters in 219 Multiple Sclerosis S. Gas, C. Caudie, C. Quincy	365
Interpretation of the Protein Profile of Cerebrospinal Fluid in Children L. Gerbaut, G. Ponsot	369
Cerebrospinal Fluid Ferritin: Interest as Biological Marker of Central Nervous System Tumors P. Antoine, R. Later, J.C. Eynard, F. Durand, B. Marechal, C. Quincy	375
Clinical Relevance of Beta 2 Microglobulin Levels of the Cerebrospinal Fluid in Children with Acute Encephalitis E.J. Raynaud, F. Deméocq, P. Vanlieferinghen, G. Malpuech, G. Gaillard	379
Electrophoretical Patterns of Acetylcholinesterase in Cerebrospinal Fluid J.C. Frot, F. Muller, P. Giraudet	383
Cholinesterase Isoenzymes of Cerebrospinal Fluid and Guillain-Barre Syndrome A. Simplot, S. Guibaud, A. Mercatello, D. Robert, O. Robert	387
Lymphocytotoxic and Monocytotoxic Antibodies in Multiple Sclerosis L. Rumbach, M.M. Tongio, J.M. Warter, C. Marescaux, M. Collard, S. Mayer	391
Interest of a High Resolution Agarose Gel Electrophoresis System (Panagel ^R) with a Silver Staining Revelation in the Study of Cerebrospinal Fluid (CSF) Immunoglobulin G E. Plan, J.B. Seneterre, C. Quincy	395

Two Dimensional Electrophoresis of CSF Proteins: Electrophoresis Quality Control	
S. Gehamy, S. Reynier, C. Caudie, C. Quincy	401

SECTION VI INFLAMMATION AND MALNUTRITION

Anthropometric and Biological Characterization of Malnutrition States in Man	
--	--

C. André, S. Danière	409
----------------------------	-----

New Findings on the Role of Zinc as a Biological Response Modifier	
--	--

S. Cunningham-Rundles	421
-----------------------------	-----

Immunodeficiency in Protein or Vitamin A Deprived Mice	
--	--

P. Binder, B. Gassies, R. Fontanges	429
---	-----

Immunological Consequences of Protein Deprivation in Primates	
---	--

S. Qazza	439
----------------	-----

Serum Thymic Factor (FTS) Contents of the Thymus in Undernourished Senegalese Children	
--	--

B. Jambon, O. Ziegler, B. Maire, G. Parent, M.C. Bene, G. Faure, A. Patris, J. Duheille	453
---	-----

The Clinico-Pathological Consequences of Severe Protein-Energy Malnutrition in Deceased Senegalese Children	
---	--

O. Ziegler, B. Jambon, G. Parent, M. Maire, R. Dardelin, M. Fall, J. Duheille	457
---	-----

Protein Profile and Thymic Function in Protein-Energy Malnutrition without Surimposed Infections: Anorexia Nervosa	
--	--

F. Bleiberg, S. Wade, D. Lemonnier, M. Dardenne, H. Flavigny, A. Mossé, J. Lubetzki, P. Chapuis, D. Roche	461
---	-----

Malnutrition in Cancer and Cachectic Patients

F. Bozzetti 465

Marker Proteins of Inflammation and Nutrition in Advanced Cancer

L. Deneux, M. Magalhaes, H. Magdelenat, P. Pouillart 477

Nutritional and Inflammatory Status in 26 Cases of Malignant Hemopathies of the Infancy

F. Bienvenu, A. Rochette, G. Souillet 481

Comparison between CRP Serum Values and Hematological Parameters for Diagnosis and Therapeutic Surveillance of Neonatal Infections

C. Benattar, D. Vauzelle, A. Lindenbaum, J.F. Magny 485

Contribution of Principal Components Analysis to the Study of Inflammatory and Nutritional Status on Intensive Care Patients

J.P. Clavel, D. Gerbet, M.C. Diemert, J. Galli, A. Galli, P. Glaser 489

Effects of Nutrition on the Post-Operative Serum Levels of Prealbumin (PA), Transferrin (T) and Fibronectin (FN)

J.F. Zazzo, B. Millat, D. Vauzelle, A. Abella 493

Surgery Induced Modifications of Plasma Protein Levels

A. Lepape, J.P. Perdrix, B. Rondelet, V. Banssillon, J. Bienvenu, H. Bernon, A. Rouillet, P. Laurent 497

Study of 8 Plasma Proteins during a Case of Severe Heat Stroke

J.P. Perdrix, A. Lepape, J.M. Grozel, V. Banssillon, J. Bienvenu, M. Manchon, H. Bernon, A. Rouillet 503

Serum Protein Profile Evolution after Sub-Total Hepatectomy

M. David, A. Lobéra, D. Marée, E. Legrand 507

Malnutrition and Immunity in Chronic Heavy Drinkers with
and without Cirrhosis
D. Vuitton, P. Rollin, P. Jeambrun, H. Allemand,
M.T. Henriet, P. Hervé, J.P. Miguet 513

Biological Nutritional Markers which Poorly Reflect the
Activity of Crohn's Disease
L. Descos, C. André, F. André, P. Landais, J. Fermanian .. 519

Prediction of Success or Failure of Parenteral Alimentation
in the Treatment of Severe Forms of Crohn's Disease and
Rectocolitis
C. André, L. Descos, N. Stremsdorfer 523

Albumin Assay with Astra 8 by a Technique Using Bromocresol
Green: Quality Criteria, Comparison with Nephelometry
J. Oglobine, B. Bouchet, Z. Pourshaidi, A. Desplaces 527

Quantitative Estimate of the Nutritional Status Through
the Measurement of the Electrical Body Impedance
A.L. Thomasset, C. Rouillet, J. Lenoir 531

SECTION VII MARKER PROTEINS IN EXPERIMENTAL MODELS OF INFLAMMATION

Characterization of Circulating Alpha-1-Acid-Glyco-
protein in Normal and Inflammatory Mice
P.M.H. Heegaard, J. Bienvenu, I. Sabbagh, A. Delvil,
P. Laurent, T.C. Bøgg-Hansen 539

The Inflammatory Reaction of the Developing Rat: Responses
of Serum Steroid Hormones and Proteins
H. Zouaghi, L.Savu, R. Vranckx, M.E. Martin, E.A. Nunez .. 549

The Effects of Ethinyl-Oestradiol and of Acute Inflamma-
tion on the Plasma Level of Rat Alpha 1-Acid Glyco-
protein and on the Cell-Free Translation of its Hepatic
mRNA
M. Diarry-Mehrpour, J. Bourguignon, I. Leroux-Nicollet,
D. Vercaigne, D. Biou, M. Hiron, J.P. Lebreton 553

Evidence for the Identity Between Alpha 1-Cysteine-Proteinase-Inhibitor and Alpha 1-Acute-Phase Globulin in Rat Serum	
F. Esnard, L. Wibissono, C. Lombart, F. Gauthier	557
Changes in Concentration of Five Rat Serum Proteinase-Inhibitors During Experimental Diabetes. Possible Relevance to Non Enzymatic Glycosylation	
F. Esnard, A. Lepape, W.T. Stauber, J.D. Guitton, F. Gauthier	561
Acute Phase Reactants, Thromboxane and Prostacyclin During Calcium Pyrophosphate-Induced Pleurisy in the Rat	
M. Tissot, M. Solier, J.P. Giroud, M. D'Asnière, R. Engler	565
Study of the Glycosylated Variants of Chicken Haptoglobin	
F. Delers, M. Domingo, Y. Rondeau, R. Engler	569
Evidence for the Presence in Chicken Plasma of a Ligand for Haptoglobin which Differs from Hemoglobin	
F. Delers, M. Domingo, Y. Rondeau, R. Engler	575
Effect of an Acute Inflammatory Reaction on the Haptoglobin, Albumin, Cytochrome P-450 Contents and Glucose-6-Phosphatase Activity in Hepatic Microsomal Fractions in the Rat	
J.L. Mahu, G. Feldmann, R. Engler	581
Circadian Variation in PMN-Migration Induced by Live BCG in Swiss Mice	
J.P. Bureau, L. Garrelly, M. Coupé, G. Labrecque	585
 SECTION VIII LECTINS	
Introductive Notes	
M. Caron, A. Faure	591

Part 1: Lectins as Tools

- The Use of Lectins to Study Changes in Rat Membrane Glycoproteins Induced by Oral Contraceptives
 B. Toor, L. McGregor, J. McGregor, S. Renaud,
 K.J. Clemetson 597
- Identification of Cytoplasmic and Membrane Platelet Glycoproteins Using a Combination of SDS-Polyacrylamide Gel Electrophoresis and ^{125}I -Labelled Lectins
 P. Clezardin, J.L. McGregor, E. James, M. Dechavanne,
 K.J. Clemetson 601
- Characterization of Human Epidermal Glycoproteins Recognized by the Lectins Con A and PNA
 P.W. Ledger, A. Réano, J.Y. Bonnefoy, J. Thivollet 605
- Fluorescent Lectins and Quantitative Microscopy
 M.A. Deugnier, X. Albe, J.C. Bisconte 609
- Effects of Serum on Lectin-Induced Lymphocyte Proliferation
 P.J. Neveu, D. Perdoux 613
- Concanavalin A and Prothrombin Complex
 M. Coulet, M.J. Bezou, P. Travade 615
- Modification of Thymidine Transport in Lectin-Stimulated Lymphocytes
 P. Beaudry, A. Sharif, Y. Goussault 619
- Induction of a Thymidine Metabolism Enzyme in Human Lymphocytes Stimulated by the Robinia pseudoacacia Lectin
 A. Sharif, P. Beaudry, Y. Goussault 621
- Lectins of Robinia pseudoacacia
 J. Wantyghem, C. Goulut, J.P. Frénoy, Y. Goussault 625

Specificity of Human Plasma Fibronectin Towards
Biomaterials

M. Caron, A. Faure, D. Gulino, C. Boisson,
J. Jozefonvicz 627

Study of the Glycosylated Populations of Plasma Alpha
1-Acid Glycoprotein in Human Breast Cancer Patients
Treated with Tamoxifen

I. Leroux-Nicollet, J.P. Lebreton, M. Hiron, F. Sauger,
C. Veyret, P. Bastit 631

Physico-Chemical and Biochemical Characteristics of the
Con-A Reactive and Non Reactive Molecular Variants of
Human Alpha 1-Acid Glycoprotein

I. Leroux-Nicollet, M. Hiron, M. Fontaine, J.P. Lebreton,
J.P. Kerckaert, B. Bayard 635

Part 2: Biological Functions of Lectins

Biological Functions of Lectins

M. Caron, M.A. Deugnier, R. Joubert, P.P. Rouge 641

Localization and Biosynthesis of Lathyrus ochrus
Seeds Lectin

C. Boisseau, H. Causse, A. Moisand, D. Père,
B. Sousa-Cavada, P. Rougé 651

Surface and Total Receptors for Asialoglycoproteins in
Hepatocytes from Diabetic Rats

G. Durand, M. Dodeur, J.P. Dumont, S. Coumoul,
J. Agneray, J. Féger 655

Part 3: Affinity and Specificity of Lectins

Lectin(s) - Ligand(s) Interactions

J.P. Frénoy 661

A Comparative Study of Affinity Constants Measured by
Different Methods, Between Peanut Lectin and Sugars
with Galactosyl Modified on C(6) or C(1)

J. Ohanessian, M. Caron 665

Effect of pH on Binding Properties of Peanut Agglutinin
(PNA)

M. Decastel, J.P. Frénoy 671

Use of Lectins to Examine the Microheterogeneity of Rat
Hemopexin

N. Bernard, R. Vranckx 673

AUTHOR INDEX 679

SUBJECT INDEX 683

ELASTASE- α_1 PROTEINASE INHIBITOR COMPLEX (E- α_1 PI) AND C-REACTIVE PROTEIN (CRP): EARLY INDICATORS OF INFLAMMATORY PROCESSES.

Marianne Jochum¹, Karl-Heimo Duswald², Hartmut Dittmer² and Siegfried Neumann³

Dept. of Clin. Chem. and Clin. Biochem.¹ of the Surgical Clinics², University of Munich, D-8000 Munich 2

Biochem. Research E. Merck³, D-6100 Darmstadt 1

Introduction

In the course of inflammatory processes stimulation of phagocytosis and production of acute phase reactants are closely connected. Whereas acute phase proteins are synthesized *de novo* by the liver cells, lysosomal enzymes of phagocytes are *performed* and can be released immediately into the circulation during frustrated phagocytosis or cell disintegration. In this way, especially lysosomal proteinases from PMN granulocytes like elastase (E) may cause destructive processes before they are inactivated by plasma proteinase inhibitors, e.g. α_1 -proteinase inhibitor (α_1 PI). Increased levels of the E- α_1 PI complex should be, therefore, a clear indication of the involvement of lysosomal proteinases in the inflammatory response (1).

Material and Methods

Using a recently developed enzyme-linked immunoassay (2) we determined the plasma levels of E- α_1 PI in 41 patients subjected to major abdominal surgery as well as in 27 patients suffering from multiple trauma. The acute phase reactants C-reactive protein (CRP), α_1 -antichymotrypsin (α_1 AC) and C1-inactivator (C1 INA) were evaluated by radial immunodiffusion (LC- or M-Partigen, Behringwerke Marburg, FRG); α_1 -proteinase inhibitor

(α_1 PI) and α_2 -plasmin inhibitor (α_2 PI) were measured by their inhibitory action on the target enzyme using chromogenic peptide substrates (Chromozym Try, Boehringer Mannheim FRG and S-2251, Kabi Stockholm, Sweden, respectively).

Results and Discussion

Septicemia

Thirty of 41 patients subjected to major abdominal surgery suffered from septicemia during the postoperative phase. Of these patients 14 survived the infection (group B) whereas the other 16 died as a direct result of septicemia (group C). The 11 patients without postoperative infection served as controls (group A).

Abdominal surgery (Fig. 1) was followed by an increase of E- α_1 PI up to 3-fold of the mean standard value (60 to 110 ng/ml). Patients suffering from preoperative infections (6 out of 16 in group C), showed already significantly elevated preoperative E- α_1 PI levels. Immediately after surgery, a slight decrease was observed, probably due to elimination of the infection focus. Before onset of sepsis, the E- α_1 PI concentrations of groups B and C showed a moderate elevation but no significant changes compared to the early postoperative levels. However, at the beginning of septicemia a highly significant increase of the E- α_1 PI levels could be detected, up to 6-fold in group B and up to 10-fold in group C. Peak levels were found to be higher than 2 500 ng/ml in both groups. The E- α_1 PI levels of septic patients who recovered showed a clear tendency towards normal values. In patients with persisting septicemia, high levels of E- α_1 PI were measured until death.

Daily measurements of pre- and early postoperative values of CRP and E- α_1 PI in the control and septicemia groups designed both factors as being similarly sensible to the inflammatory stimulus (Fig. 1). In contrast to the E- α_1 PI levels, however, the CRP levels did not allow discrimination of the severity of




Fig. 1. Plasma levels of E- α_1 PI complex and CRP in patients with major abdominal surgery.

A = without pop. I.

B = survival of pop. I.

C = death due to pop. I.

(pop. I. = postoperative infection).

Data are given as mean values for the day before operation, the day after operation, the period before onset of sepsis and the course of septicemia. The last determinations were done on the days of discharge (D) in group A, recovery (R) in group B, and before death (†) in group C. Normal range (nr) of E- α_1 PI: 60-110 ng/ml.

the infection in the later postoperative phase, neither at onset nor during septicemia in both infected groups; only the last values were in agreement with clinical observations. Obviously, liberation of lysosomal elastase, probably due to an enhanced action of endotoxins on granulocytes throughout septicemia, does reflect more specifically this severe infection compared to CRP, which is supposed to play a central role in unspecific host defence (3).

Moreover, the plasma proteinase inhibitors (α_1 AC, C1 INA, α_1 PI and α_2 PI) representing acute phase proteins did also not reflect the morbid state, likely due to an overlap of production and consumption of these glycoproteins (data not shown).

Multiple trauma

In a preliminary study release of granulocytic elastase into plasma was followed up every 4 hours in patients who suffered from multiple trauma. The increase of the E- α_1 PI complex up to 16 hours after accident coincided clearly with the severity of the injury (Fig. 2), the degree of injury being established on the basis of a hospital internal scale ranging from 1-20 points. Group I patients (5 to 7 points) showed a maximal increase of E- α_1 PI up to 5-fold above normal values and group II patients (9 to 11 points) up to 10-fold. In group III (14 to 17 points) peak levels higher than 20-fold above normal were measured. During the further observation period (up to 100 h) a significant decrease of E- α_1 PI plasma levels towards normal values was observed in all patients.




Fig. 2. Plasma levels of E- α_1 PI complex and CRP in patients after multiple trauma. On the basis of a hospital internal scale with 20 points (HISP) patients were allied to 3 groups reflecting the severity of injury: I mild ; II severe; III highly severe.

Group	No. of patients	HISP
I	12	6.3 \pm 0.6
II	11	10.0 \pm 1.0
III	4	15.3 \pm 1.9

Normal range of E- α_1 PI:
60 - 110 ng/ml

Maximal increase of CRP levels was observed normally between 20 and 40 h after accident (group I and II in Fig. 2). In a few cases (group III) maximal CRP values were measured up to 88 h after trauma (Fig. 2). Within the observation period, the CRP levels showed neither a statistically significant correlation to the severity of the injuries nor a clear tendency towards normalization. The same holds true for the plasma proteinase inhibitors responding as acute phase proteins (data not shown). In contrast to results published recently (4), we could so far not find a relationship between the amount of CRP in plasma and posttraumatic complications after cranio-cerebral injuries.

Conclusions

Although of all known acute phase proteins CRP rises most dramatically and rapidly, the given data demonstrate that complexed elastase ($E-\alpha_1PI$) reflects the severity of an inflammatory response clearly earlier and more specifically. Hence, compared to lysosomal elastase increased production of acute phase proteins, at least of CRP, represents a delayed and less specific answer of the organisms to the primary inflammatory stimuli during diseases such as septicemia and multiple trauma.

References

1. Jochum, M., Duswald, K.H., Hiller, E., and Fritz, H.: In: Selected Topics in Clinical Enzymology; Walter de Gruyter and Co., Berlin, New York, 1983, 85-100.
2. Neumann, S., Hennrich, N., Gunzer, G., and Lang, H.: J. Clin. Biochem. 19, 232 (1981).
3. Kushner, I., Gewurz, H., Benson, M.D.: J. Lab. Clin. Med. 97, 739-749 (1981).
4. Engler, E.: Laboratoriumsblätter 33, 1-8 (1983).

AUTHOR INDEX

- Abella, M. 493
 Adam, A. 57,79
 Agneray, J. 655
 Albe, X. 609
 Allen, R.C. 43
 Allemand, D. 513
 André, C. 409,519,523
 André, F. 519
 Antoine, P. 375
 Arnaud, P. 43,181,319

 Banssillon, V. 497,503
 Barbier, M. 251
 Barbier, Y. 251
 Bastit, P. 631
 Bata, J. 207
 Bayard, B. 635
 Beaudry, P. 619,621
 Benattard, C. 485
 Bene, M.C. 453
 Benzerara, O. 231
 Bernard, N. 673
 Bernon, H. 497,503
 Bezou, M.J. 615
 Bienvenu, J. 71,497,503,539
 Bienvenu, F. 481
 Bieth, J.G. 227
 Binder, P. 429
 Biot, N. 243
 Biou, D. 553
 Bisconte, J.C. 609
 Bleiberg, F. 461
 Bøg-Hansen, T.C. 539
 Boisseau, C. 651
 Boisson, C. 627
 Boisson, R.C. 251
 Bonnefoy, J.Y. 605
 Bouchet, C. 527
 Boudier, C. 227
 Bourg, P. 305
 Bourguignon, J. 553
 Bozzetti, F. 465
 Brune, J. 223,231,255
 Bureau, J.P. 585

 Calay, G. 79
 Cambillau, M. 247
 Carli, A. 75
 Caron, M. 591,627,641,665
 Cartier, B. 305

 Caudie, C. 345,359,365,401
 Causse, H. 651
 Chambers, R.E. 47
 Chapuis, P. 461
 Chapuis-Cellier, C. 255
 Chauvot, P. 223
 Chazalotte, J.-P. 235,239
 Clavel, J.P. 489
 Clemetson, K.J. 597,601
 Clezardin, P. 601
 Colin, B. 71
 Collard, M. 391
 Collombel, C. 305
 Confravreux, C. 319
 Cordier, G. 207,223
 Cordier, J.-F. 219,223,231,255

 Coulet, M. 615
 Coumoul, S. 655
 Coupé, M. 585
 Cunningham-Rundles, S. 421
 Crystal, R.G. 219,261

 Damas, J. 57
 Danière, S. 409
 Dardelin, R. 457
 Dardenne, M. 461
 D'Asniere, M. 565
 David, M. 507
 Davril, M. 171
 Decastel, M. 671
 Dechavanne, M. 601
 De Fenoyl, O. 247
 De Hertogh, H. 79
 Delers, F. 135,569
 Delvil, A. 71,539
 Delmas, P.D. 281
 Deméocq, F. 379
 Deneux, L. 477
 Descos, L. 519,523
 Desplaces, A. 527
 Deugnier, M.A. 609,641
 Diarra-Mehrpour, M. 553
 Diemert, M.C. 489
 Dittmer, H. 51
 Dodeur, M. 655
 Domingo, M. 569
 Duchassaing, D. 247
 Duheille, J. 453,457
 Dumont, J.P. 655

- Durand, F. 375,655
 Duswald, K.H. 51
 Emerson, D.L. 43
 Engler, R. 135,203,565,
 569,581
 Ers, P. 57,79
 Esnard, F. 203,557,561
 Eynard, J.C. 375
 Fall, M. 457
 Faulk, W.P. 139
 Faure, A. 453,591,627
 Faymonville, M.E. 57
 Féger, J. 655
 Feldmann, G. 15,581
 Fermanian, J. 519
 Fiedel, B.A. 99
 Fischer, E. 135
 Flavigny, H. 461
 Fontaine, M. 635
 Fontanges, R. 429
 Freney, O. 345,359
 Frénoy, J.-P. 625,661,671
 Frot, J.C. 383
 Gaillard, G. 379
 Galli, A. 489
 Galli, J. 489
 Garcia, I. 251
 Garrelly, L. 585
 Gas, S. 359,365
 Gassier, B. 421
 Gauthier, F. 203,557,561
 Gehamy, S. 401
 Gerbault, L. 369
 Gerbet, D. 489
 Gianazza, E. 181
 Gilly, R. 251
 Gindre, D. 243
 Giraudet, P. 383
 Giroud, J.P. 565
 Glaser, P. 489
 Goulut, C. 625
 Goussault, Y. 619,621,625
 Grozel, J.M. 503
 Guérot, C. 75
 Guibaud, S. 387
 Guitton, J.D. 561
 Gulino, D. 627
 Hara, I. 295
 Harf, R. 243
 Hayem, A. 171
 Heegaard, P.M.H. 539
 Henriët, M.T. 513
 Hervé, P. 513
 Hiron, M. 553,631,635
 Hsi, B.-L. 139
 Hulot, M. 57
 Izui, S. 295
 Jacquot, J. 235,239
 Jambon, B. 453,457
 James, E. 601
 Jeambrun, P. 513
 Jochum, M. 51
 Josefowicz, J. 627
 Joubert, R. 641
 Kazatchkine, M. 135
 Kerckaert, J.P. 635
 Kleinknecht, D. 75
 Kushner, I. 3
 Labrecque, G. 585
 Lachneche, B. 223
 Lafont, P. 251
 Lahet, C. 71
 Laine, A. 171
 Lamy, M. 57
 Landais, P. 519
 Lasne, Y. 231
 Later, R. 375
 Latour, M. 207
 Laurent, P. 43,71,497,539
 Lebreton, J.P. 553,631,635
 Leclerc, P. 247
 Lecocq, J. 311
 Lecocq, N.A. 311
 Lecomte, J. 57
 Ledger, P. 605
 Legrand, E. 507
 Lemonnier, D. 461
 Lenoir, J. 531
 Lepape, A. 497,503,561
 Leroux-Nicollet, I. 553,
 631,635
 Lindenbaum, A. 485
 Lobéra, A. 507
 Loire, R. 223
 Lombart, C. 557
 Lowenthal, A. 339
 Lubetzki, J. 461
 Magdelenat, H. 477
 Magny, J.F. 485

- Mahu, J.L. 581
 Maire, B. 453,457
 Malengreaux, P. 57
 Malgalhaes, M. 477
 Malpuech, G. 379
 Manchon, M. 503
 Maréchal, B. 375
 Maréchal, F. 243
 Marée, D. 507
 Marescaux, C. 391
 Martin, M.E. 549
 Mathian, J. 251
 Mathieu, M. 305
 Mayer, S. 391
 McGregor, J. 597,601
 McGregor, L. 597
 Mercatello, A. 387
 Miquet, J.P. 513
 Millat, B. 493
 Moisand, A. 651
 Mornex, F. 223
 Mornex, J.F. 223,261
 Mossé, A. 461
 Muller, F. 383

 Neumann, S. 51
 Neveu, P.J. 613
 North, M.L. 311
 Nunez, E.A. 75,549

 Oglobine, J. 527
 Ohanessian, J. 665

 Pagano, M. 203
 Pages, J. 223
 Parent, G. 453,457
 Paris, M. 247
 Patris, A. 453
 Pauli, G. 227
 Pelletier, A. 227
 Penet, A. 255
 Perdoux, D. 613
 Perdrix, J.P. 497,503
 Père, D. 651
 Perrin, L.F. 71
 Perrin-Fayolle, M. 243
 Plan, E. 395
 Ponsot, G. 369
 Pontet, M. 135
 Pouillart, P. 477
 Pourshaidi, Z. 527
 Puchelle, E. 235,239
 Putnam, F.W. 25

 Quazzaz, S. 439
 Quincy, C. 355,359,365,
 375,395,401

 Raynaud, E.J. 379
 Réano, A. 605
 Rebattu, J.P. 71
 Renaud, S. 597
 Revillard, J.-P. 207,223
 Reynier, S. 401
 Reynolds, H. 153
 Robert, D. 387
 Robert, O. 387
 Roche, D. 461
 Rochette, A. 481
 Rollin, P. 513
 Rondeau, Y. 569
 Rondelet, B. 497
 Roth, M. 311
 Roth-Fouret, C. 153
 Rougé, P. 651
 Rouge, P.P. 641
 Rouillet, A. 497,503
 Rouillet, C. 531
 Rowe, I. 273
 Ruddy, S. 125
 Rumbach, L. 391

 Sabbagh, I. 539
 Sadoul, P. 235,239
 Sauger, F. 631
 Savu, L. 75,549
 Senneterre, J.B. 395
 Servoz, G. 355
 Sharif, A. 619,621
 Simplot, A. 387
 Solier, M. 565
 Souillet, G. 481
 Sousa-Cavada, B. 651
 Stauber, W.T. 561
 Stremdsorfer, R. 523

 Thivolet, A.L. 605
 Thomasset, A.L. 531
 Tissot, M. 565
 Tongio, M.M. 391
 Toor, B. 597
 Touraine, F. 345,355
 Touraine, R. 231
 Tournier, J.M. 235,239
 Tran Quang, N. 135
 Travade, P. 615

Vanlieferinghen, P. 379
Vauzelle, D. 485,493
Vercaigne, D. 553
Vercoustre, B. 243
Vergnon, J.-M. 223,255
Veyret, C. 631
Vincent, M. 223
Vranckx, R. 549,673
Vuitton, D. 513

Wade, S. 461
Wantyghem, J. 625
Warter, J.T. 391
Whicher, J.T. 47,89
Wibissono, L. 557
Wiesendanger, T. 223

Yeh, C.-J. 139

Zazzo, J.F. 493
Ziegler, O. 453,457
Zouaghi, H. 75,549

SUBJECT INDEX

- Abortion (recurrent spontaneous) 139.
- Acute Phase:
- alpha 1 globulin 557.
 - reaction (mouse) 295.
 - reaction (rat) 549, 673
 - reactant proteins (APP) 3, 15, 25, 47, 57, 89, 135, 305, 481, 507, 519, 549, 557, 561, 565.
 - APP - negative 3.
- Affinity constant 665.
- Affino immunoelectrophoresis 673.
- Albumin 365, 513, 519, 527, 581.
- Alpha 1-acid glycoprotein 47, 71, 99, 539, 553.
- Alpha 1-antitrypsin 207.
- Alpha 1-cystein proteinase inhibitor 557.
- Alpha 1-proteinase inhibitor 251, 561.
- Alpha 2 macroglobulin 207.
- Alveolar macrophage 153, 243.
- Amyloid 3, 47, 273.
- Amyloidosis 47.
- Animal lectins
- Anorexia nervosa 461.
- Anthropometry
- standard 409, 457.
- Antigen antibody 295.
- Asialoglycoprotein 655.
-
- BCG 585.
- Beta interferon
- treatment 3, 369.
- Beta 2-microglobulin 247, 379.
- Binding sites
- copper 25, 575.
- Bone diseases 281.
- Bone GLA Protein 281.
- Brain tumor 375.
- Bronchial superinfection 239.
- Broncho-alveolar lavage (BAL) 223, 231, 243.
-
- Calcium metabolism 281.
- Cancer 465, 477.
- Cardiac disease 75.
- Cathepsin
- G 171.
 - L 203.
- Cellular enzymes 153.
- Cerebro Spinal Fluid (CSF) 319, 345, 355, 359, 365, 369, 375, 379, 383, 387, 391, 395, 401.
- Ceruloplasmin 25.

- Chemotactic factors 153, 219.
- Chicken 575.
- Cholinesterase inhibitor 383.
- Cigarette smoker 227.
- Circadian rhythms 585.
- Coagulation 99, 597.
- Complement
 - alternative pathway 135, 369.
- Concanavalin A (Con-A lectin) 597, 601, 605, 613, 615, 661.
- Connective tissue disease 273.
- Connective tissue repair 89.
- Copper
 - binding sites 489.
- Cortisol 75, 461.
- Crohn's disease 519, 523.
- C-Reactive Protein 3, 43, 47, 51, 71, 99, 273, 477, 648.
- Cystic fibrosis 239, 251.
- Cytochrome P-450 581.
- Cytokeratin 605.

- Delayed hypersensitivity 409.
- Deoxythymidine 619, 621.
- Dietary condition 429.

- Elastase
 - alpha 1 proteinase inhibitor 51.
- Electrophoresis
 - two dimensional 401.
- Emphysema 223.
- Encephalitis 379.
- Energy balance 465.
- Enzyme immunoassay 375.
- Epidemiology 319.
- Epidermis glycoproteins 605.
- Experimental diseases
 - diabetes 561.
 - inflammation 539.

- Ferritin 375.
- Fibrinolytic enzyme 99, 231.
- Fibronectin 243, 341, 493, 627, 647.
- Fibrin 99.
- Fibrosing alveolitis 223.
- Fluorometer 609.

- Galactosides 665.
- Gallium scanning 223.
- Gamma carboxyglutamic 281.
- Genetics 319.
- Glucose 6 phosphatase 581.
- Glycosylation
 - non enzymatic 553.

Glycoprotein
 membrane
Guillain Barre 387.

Haptoglobin 71, 575, 581.
Hemolytic plaque test 15.
Hemopathy 481.
Hepatectomy 507.
HLA 139.
Human lectins 339.
Hyperimmunization and hypersensitivity 339, 429.

Ideal weight 409.
Idiopathic pulmonary fibrosis 223.
Immediate hypersensitivity 429.
Immune regulation 89
Immune response 421, 429, 453, 513.
Immunoaffinoelectrophoresis 539, 575.
Immunochemical quantitation 171.
Immunolectrophoresis 255, 539.
Immuno fluorescence 15, 139.
Immunoglobulins
 IgG 247, 339, 365.
Immunological disorder 429.
Immuno-peroxidase 15.
Impedency 531.
Inflammatory bowel diseases 47.
Intensive care monitoring 489.
Interleukin I 3.
Internal duplication 25.
Isoelectric
 focusing 43, 255.
 points 43, 255, 401
Isoenzymes 383, 387.

Joint diseases 305, 311.

Kallikrein 57, 79.
Kininogen 57, 79.
Kinins 57.
Kwashiorkor 453, 457.

Lathyrus Ochrus lectin 651.
Lectins
 biological functions 641.
 biosynthesis 597, 601.

- 125I labelled 597, 601.
- fluorescent 609.
- ligand 661.
- purification 661.
- Lens culinaris (LCH lectin) 597, 601.
- Leukocytes 345, 585.
- Leukocyte endogenous pyrogen 3.
- Limulus polyphemus 661.
- Liver 3, 15, 203, 235, 507, 513.
 - microsomes 581.
 - steatosis 457.
- Lung diseases 153.
- Lung fibrosis 231.
- Lymphoblastogenesis 613, 619, 621.
- Lymphocyte response 207, 421.
- Lymphocytes subsets 319, 355.
- Lymphocytotoxic antibodies 391.

- Malnutrition 409, 453, 457, 461, 465, 477, 481, 489, 513.
- Marasmus 453, 457.
- Materno-foetal relationships 139.
- Meconium 291.
- Mice (alpha 1-acid glycoprotein) 539
- Monocytotoxic antibodies 391.
- Monokines 3, 89.
- mRNA 553.
- Multiple Sclerosis 319, 365, 369, 391.
- Multiple Trauma 51, 395.

- Natural Killer 421.
- Negative APP 3.
- Nephelometry 79, 527.
- Non steroidal anti inflammatory drugs 71.

- Oestrogen 553.
- OKT 355.
- Oligoclonal bands 365.
 - IgG 319.
- Oral contraceptive 597.
- Osteocalcin 281.
- Oxidant 219, 291.

- PAGE (polyacrylamide gel electrophoresis) 383, 601.
- Parenteral alimentation 493, 523.
- Peanut Lectin (PNL-Rh) 605, 609, 665, 671.
- Pediatric diseases 379, 481.
- Peritonitis 493.
- Phagocytosis 89.
- Phytohemagglutinin (PHA lectin) 613.
- Platelets
 - aggregation 99, 597, 601, 615.
 - membrane glycoprotein 601.
 - release functions 99.

Pleural effusion 565.
Prealbumin 369, 477, 493.
Pregnancy 159.
Prostaglandin 565.
Protase-antiprotease 89, 171, 203, 207, 219.
Protein metabolism 465.
Protein sequence (ceruloplasmin) 25.
Protein ligand interactions 575.
Proteinase inhibitor 203.

Prothrombin 615.
Prothrombin complex factors 615.
Pulmonary alveolitis 219.

Quick time 615.

Radio immuno assay 79, 281.
Rat 549, 553, 557, 561, 581, 597.
 alpha l-acid glycoprotein 553.
 developing 549.
 hepatocyte 553, 655.
 platelet 597.
 transcortin 549.
Rectocolitis 523.
Renal disease 75.
Retinol Binding Protein 477.
Retroviral GP70:I 295.
Rheumatoid arthritis 47, 905, 311.
Robinia Pseudoacacia lectin 619, 621, 625.

Sarcoidosis 243, 247.
Secretion 15.
Septicemia 51.
Serum Amyloid A Protein (SAA) 47, 273.
Serum Amyloid P Component (SAP) 99, 273, 648.
Silver staining 253, 395.
Skin fold 409.
Sputum 239.
Statistical analysis 439.
Synovial fluid 305.
Systemic lupus erythematosus (SLE) 295.

Thymic factor (serum) 453, 461.
Titration curves 43.
Transcortin 75.
Transferrin 477, 493.
Trophoblast 139.

Vaccination 429.

Wheat germ agglutinin (WGA lectin) 597, 601.

Zinc 421, 461, 489.